Decision-Grade Biomanufacturing Enablement
Boston BioKatalyst delivers a suite of integrated solutions designed to eliminate friction in early and mid-stage biomanufacturing. We remove the burden of partner search, qualification, and coordination by combining a curated CDMO network, standardized workflows, and AI-assisted decision support into a single execution layer.
Our role is simple: translate scientific intent into manufacturable reality—faster, cleaner, and with fewer false starts.
CDMO Discovery & Partner Routing
From uncertainty to execution clarity
Selecting the right CDMO is one of the highest-impact decisions in development—and one of the least standardized. Capability lists, cold outreach, and one-off recommendations rarely account for capacity, quality posture, or tech-transfer readiness.
Our solution
We map your technical requirements, timelines, and regulatory targets, then route your program through a curated network of pre-qualified CDMOs to produce a short list of true execution fits.
Outcome
- Faster feasibility assessments
- Shortlists based on real manufacturing alignment
- Reduced time spent sourcing and qualifying partners
AI-Assisted Matchmaking & Decision Support
Matching informs. Routing commits.
Most “AI matchmaking” tools stop at similarity scoring. BioKatalyst is designed for manufacturing reality.
Our solution
Using a standardized RFQ, we apply AI-assisted decision support to score CDMOs across factors that actually determine success: platform fit, analytical depth, scale range, containment level, timeline reliability, and regulatory history. These scores are combined with human judgment—capacity windows, communication quality, and prior execution outcomes—to finalize routing decisions.
Outcome
- Apples-to-apples partner comparisons
- Fewer late-stage surprises
- Faster, more confident go/no-go decisions
Standardized RFQs & Quote Normalization
Clear inputs. Comparable outputs.
Unstructured RFQs create wasted cycles and subjective decision-making.
Our solution
We deploy a standardized RFQ framework designed to capture the minimal, high-signal inputs that matter for manufacturability: target product profile, critical quality attributes, intended scale, assay readiness, stability expectations, timelines, and regulatory constraints.
Because every project uses the same structure, proposals become directly comparable.
Outcome
- Reduced back-and-forth with vendors
- Cleaner quotes and timelines
- Faster internal alignment
Process Development & Tech-Transfer Readiness
Manufacturability as a design constraint
Many programs fail not because the science is wrong, but because execution readiness is deferred too long.
Our solution
We support early process development routing, scale-down strategy alignment, and tech-transfer readiness by coordinating documentation expectations, analytical scope, and pilot planning before contracts are finalized.
Outcome
- Smoother tech transfers
- Reduced rework during scale-up
- Earlier visibility into execution risk
Analytical Strategy & Quality Alignment
Quality posture before it becomes a problem
Quality systems and analytics determine downstream value—but are often treated reactively.
Our solution
We help align analytical strategy, assay readiness, comparability logic, and phase-appropriate validation expectations with the selected CDMO’s quality system and regulatory posture.
Outcome
- Fewer GMP surprises
- Stronger inspection readiness
- Cleaner CMC narratives for investors and regulators
Program Coordination & Early Execution Support
One point of contact. Fewer moving parts.
Fragmented communication slows programs and increases risk.
Our solution
BioKatalyst acts as a centralized coordination layer during early execution—managing NDAs, secure data exchange, introductions, initial documentation checks, and milestone tracking across parties.
Outcome
- Reduced administrative burden on scientific teams
- Tighter timelines
- Clear accountability across partners
Modalities & Manufacturing Coverage
Routed through a specialized network
Because Boston BioKatalyst operates as a network, we can support a broad range of programs by routing each to the appropriate execution environment.
Coverage includes (partner-dependent):
Biologics & Recombinant Proteins
Monoclonal antibodies, bispecifics, fragments, fusion proteins, enzymes, cytokines, hormones, scaffold proteins, and difficult-to-express constructs.
Microbial Platforms
E. coli, Pichia pastoris, Saccharomyces, Bacillus and other microbial systems; inclusion body workflows; refolding; microbial DSP.
Mammalian Platforms
CHO and HEK expression, upstream and downstream process development, intensified processes, purification strategies, and comparability planning.
Cell & Gene Therapy
AAV, lentiviral and retroviral vectors, plasmid DNA supply chains, gene-modified cell therapy support, and associated analytics and tech transfer.
Vaccines & Immunotherapies
Recombinant antigens, subunit vaccines, viral vectors, VLPs, and immunostimulatory biologics.
Nucleic Acids & Novel Modalities
Plasmid DNA, IVT templates, select oligonucleotide workflows, extracellular vesicles (EVs/exosomes), and emerging delivery systems (partner-dependent).
Why BioKatalyst Works
Biomanufacturing success depends on coordination, not just capability. Boston BioKatalyst treats partner selection as an execution problem—measured, comparable, and routed through a system that learns from real outcomes.
We don’t replace scientific judgment.
We remove noise, compress decision cycles, and align execution early—when it matters most.
Ready to move faster?
Submit your RFQ and receive a vetted short list plus an actionable next-step plan.